EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer

Nicholas C Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang und 10 weitere

New England Journal of Medicine · 31.10.2024 · 391 (17) · 1584-1596

DOI: 10.1056/nejmoa2404625 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 31.10.2024. Verfasst von Nicholas C Turner und 21 weiteren Autor:innen. Beteiligte Einrichtung: From the Royal Marsden Hospital and Institute of Cancer Research (N.C.T.) and the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Qu…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Male. Die Arbeit wurde bisher 321-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: F. Hoffmann–La Roche, F. Hoffmann-La Roche Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesBreast Neoplasms, MalePhosphoinositide-3 Kinase InhibitorsAdultAgedFemaleHumansMiddle AgedDouble-Blind MethodKaplan-Meier EstimateMutationPiperazinesProgression-Free SurvivalPyridinesMaleImidazolesOxazoles

Substanzen

Class I Phosphatidylinositol 3-KinasespalbociclibPIK3CA protein, humanPiperazinesPyridinesinavolisibPhosphoinositide-3 Kinase InhibitorsImidazolesOxazoles

Autor:innen und Institutionen

  • From the Royal Marsden Hospital and Institute of Cancer Research (N.C.T.) and the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London (P. Schmid), London, and Roche, Welwyn G…

Förderung

  • F. Hoffmann–La Roche
  • F. Hoffmann-La Roche Ltd

Zitieren

APA

Turner, N. C., Im, S. A., Saura, C., Juric, D., Loibl, S., Kalinsky, K., Schmid, P., Loi, S., Sunpaweravong, P., Musolino, A., Li, H., Zhang, Q., Nowecki, Z., Leung, R., Thanopoulou, E., Shankar, N., Lei, G., Stout, T. J., Hutchinson, K. E., …, & Jhaveri, K. L. (2024). Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer. New England Journal of Medicine, 391(17), 1584-1596. https://doi.org/10.1056/nejmoa2404625

Vancouver

Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer. New England Journal of Medicine. 2024;391(17):1584-1596. doi:10.1056/nejmoa2404625

BibTeX
@article{Turner2024,
  author = {Turner, Nicholas C and Im, Seock-Ah and Saura, Cristina and Juric, Dejan and Loibl, Sibylle and Kalinsky, Kevin and Schmid, Peter and Loi, Sherene and Sunpaweravong, Patrapim and Musolino, Antonino and Li, Huiping and Zhang, Qingyuan and Nowecki, Zbigniew and Leung, Roland and Thanopoulou, Eirini and Shankar, Noopur and Lei, Guiyuan and Stout, Thomas J and Hutchinson, Katherine E and Schutzman, Jennifer L and Song, Chunyan and Jhaveri, Komal L},
  title = {Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {17},
  pages = {1584--1596},
  doi = {10.1056/nejmoa2404625}
}
Kostenlos starten →